Evidence map›Paper›PMID 27609240›Full record

ArticleThe American journal of psychiatry2017

Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [

Sina Hafizi, Huai-Hsuan Tseng, Naren Rao, Thiviya Selvanathan, Miran Kenk, Richard P Bazinet, Ivonne Suridjan, Alan A Wilson, Jeffrey H Meyer, Gary Remington and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Trial
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Article
  13. Microglia-neuron interactions in schizophrenia.Frontiers in cellular neuroscience · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sina HafiziFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Huai-Hsuan TsengFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Naren RaoFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Thiviya SelvanathanFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Miran KenkFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Richard P BazinetFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Ivonne SuridjanFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Alan A WilsonFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Jeffrey H MeyerFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Gary RemingtonFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Sylvain HouleFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Pablo M RusjanFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.
Romina MizrahiFrom the Research Imaging Centre and the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Departments of Psychiatry and of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto; and the Institute of Medical Science, University of Toronto, Toronto.

Funding

Imaging Neuroinflammation in Clinical high risk and SchizophreniaR01MH100043 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI MIZRAHI, ROMINA · 2014 to 2018
$1.6M
NIMH NIH HHS R01 MH100043
6 · The paper itself

Abstract

objectiveNeuroinflammation and abnormal immune responses are increasingly implicated in the pathophysiology of schizophrenia. Previous positron emission tomography (PET) studies targeting the translocator protein 18 kDa (TSPO) have been limited by high nonspecific binding of the first-generation radioligand, low-resolution scanners, small sample sizes, and psychotic patients being on antipsychotics or not being in the first episode of their illness. The present study uses the novel second-generation TSPO PET radioligand [

methodNineteen untreated patients with first-episode psychosis (14 of them antipsychotic naive) and 20 healthy volunteers underwent a high-resolution [

resultsNo significant differences were observed between patients and healthy volunteers in microglial activation, as indexed by [

conclusionsThe lack of significant differences in [

Indexed as

Image EnhancementPositron-Emission TomographyAdultAnilidesFemaleGenotypeHippocampusHumansMagnetic Resonance ImagingMaleMicrogliaMultimodal ImagingPrefrontal CortexPsychotic DisordersPyridinesReceptors, GABAAnilidesN-(2-((N-(4-phenoxypyridin-3-yl)acetamido)methyl)phenoxy)ethyl fluoridePyridinesReceptors, GABATSPO protein, humanImagingMicrogliaNeuroinflammationPETPsychosisSchizophrenia

Identifiers

PMID27609240
PMCPMC5342628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.